Efficacy and safety of calcitonin-gene-related peptide binding monoclonal antibodies for the preventive treatment of episodic migraine – an updated systematic review and meta-analysis
Abstract Background Migraine is one of the most common neurological disorders that leads to disabilities. However, the conventional drug therapy for migraine might be unsatisfactory at times. Therefore, this meta-analysis aimed to evaluate the efficacy and safety of calcitonin-gene-related peptide b...
Main Authors: | Hong Deng, Gai-gai Li, Hao Nie, Yang-yang Feng, Guang-yu Guo, Wen-liang Guo, Zhou-ping Tang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2020-02-01
|
Series: | BMC Neurology |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12883-020-01633-3 |
Similar Items
-
Monoclonal antibodies against calcitonin gene-related peptide in chronic migraine: an adjusted indirect treatment comparison
by: María del Pilar Briceño-Casado, et al.
Published: (2020-09-01) -
Efficacy and Safety of Monoclonal Antibody Against Calcitonin Gene-Related Peptide or Its Receptor for Migraine: A Systematic Review and Network Meta-analysis
by: Xing Wang, et al.
Published: (2021-03-01) -
How to integrate monoclonal antibodies targeting the calcitonin gene-related peptide or its receptor in daily clinical practice
by: Cindy Tiseo, et al.
Published: (2019-05-01) -
The effect and safety of monoclonal antibodies to calcitonin gene-related peptide and its receptor on migraine: a systematic review and meta-analysis
by: Min Hou, et al.
Published: (2017-04-01) -
Prevention of migraine with monoclonal antibodies against CGRP or the CGRP receptor
by: Hans-Christoph Diener, et al.
Published: (2020-04-01)